Dr. Goodman on the Role of PD-1 Inhibitors in T-Cell Lymphomas

Aaron Goodman, MD, discusses the role of PD-1 inhibitors in T-cell lymphomas.

Aaron Goodman, MD, hematologist/oncologist and assistant professor of medicine at the University of California, San Diego, discusses the role of PD-1 inhibitors in T-cell lymphomas.

Initially, there was a lot of enthusiasm surrounding the use of PD-1 inhibitors in patients with T-cell lymphomas, but response rates have ranged from 10% to 30%, explains Goodman. Unlike other cancers, a protein on the T-cell lymphoma tumor must be targeted in order to activate it, thus releasing a natural break on the tumor cells. Several reports have cited hyperprogression in T-cell lymphomas treated with pembrolizumab (Keytruda) and nivolumab (Opdivo), which indicates that caution needs to be used with these agents, says Goodman.

With other targets, the new drug mogamulizumab-kpkc (Poteligeo) has been approved for use in cutaneous T-cell lymphomas. Mogamulizumab-kpkc is a monoclonal antibody that targets CCR4, which is found on regulatory T cells and malignant T cells, specifically in mycosis fungoides or Sézary syndrome, according to Goodman. The agent, when used as a monotherapy, has reasonable activity that can be durable in this patient population, concludes Goodman.

Related Videos
María-Victoria Mateos, MD, PhD
Ponatinib in patients with chronic-phase chronic myeloid leukemia and the T315I mutation: 4-year results from OPTIC
John L. Marshall, MD
Petros Grivas, MD, PhD
Noopur S. Raje, MD
Atish D. Choudhury, MD, PhD
Benjamin Levy, MD
Paolo Tarantino, MD
Sujith Samarasinghe, MD
Suzanne Trudel, MSc, MD